UK Government and BioNTech to deliver cancer immunotherapies to 10,000 by 2030

Thousands of cancer patients in England are set to gain fast-tracked access to personalised cancer vaccine trials through a new National Health Service(NHS)
initiative, the Cancer Vaccine Launch Pad.

This groundbreaking service aims to find new life-saving treatments by matching eligible patients with clinical trials across the country.

The first patient to receive a personalised vaccine for bowel cancer is Elliot Phebve, a 55-year-old lecturer, treated at University Hospitals Birmingham NHS
Foundation Trust.

Phebve, diagnosed through a routine health check, underwent surgery and chemotherapy before joining the trial.

Sponsored by German biotech company BioNTech SE, the colorectal cancer vaccine trial is one of several taking place across NHS trusts.